682 related articles for article (PubMed ID: 10773225)
1. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases: pathways of induction by bioactive molecules.
Tsuruda T; Costello-Boerrigter LC; Burnett JC
Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
[TBL] [Abstract][Full Text] [Related]
4. Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation.
El Hajj EC; El Hajj MC; Voloshenyuk TG; Mouton AJ; Khoutorova E; Molina PE; Gilpin NW; Gardner JD
Alcohol Clin Exp Res; 2014 Feb; 38(2):448-56. PubMed ID: 24033327
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
6. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
8. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
9. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibition and the prevention of heart failure.
Lee RT
Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in myocardial collagen, matrix metalloproteinases, and their tissue inhibitors in the left ventricular myocardium in experimental chronic mitral regurgitation in rodents.
Corporan D; Onohara D; Hernandez-Merlo R; Sielicka A; Padala M
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1269-H1278. PubMed ID: 30141979
[TBL] [Abstract][Full Text] [Related]
12. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.
Li YY; Feng YQ; Kadokami T; McTiernan CF; Draviam R; Watkins SC; Feldman AM
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12746-51. PubMed ID: 11070088
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
16. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.
Moore L; Fan D; Basu R; Kandalam V; Kassiri Z
Heart Fail Rev; 2012 Sep; 17(4-5):693-706. PubMed ID: 21717224
[TBL] [Abstract][Full Text] [Related]
17. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
18. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
Spinale FG
Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
20. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model.
Foronjy RF; Sun J; Lemaitre V; D'Armiento JM
Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
